Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|March 21, 2017
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancerHisato Kawakami, Junko Tanizaki, Kaoru Tanaka, et al.
Therapeutic Advances in Medical Oncology|December 30, 2025
TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i>-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinibDaniel Shao-Weng Tan, Ernest Nadal, Parneet Cheema, et al.
The Oncologist|September 12, 2020
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung CancerHidetoshi Hayashi, Masakazu Ogura, Takashi Niwa, et al.
International Journal of Clinical Oncology|June 12, 2021
CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinibRyoji Kato, Hidetoshi Hayashi, Kazuko Sakai, et al.
Angewandte Chemie (International Ed. in English)|July 7, 2018
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant InhibitorJaebong Jang, Jieun Son, Eunyoung Park, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2025
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancerTakashi Kurosaki, Hiroaki Kanemura, Tomoyuki Otani, et al.
Journal for Immunotherapy of Cancer|September 15, 2019
Clinical and immune profiling for cancer of unknown primary siteKoji Haratani, Hidetoshi Hayashi, Takayuki Takahama, et al.
Oncotarget|October 22, 2016
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1Yoshikane Nonagase, Kimio Yonesaka, Hisato Kawakami, et al.
Cancer Science|September 2, 2016
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanibMasaaki Hibi, Hiroyasu Kaneda, Junko Tanizaki, et al.
Scientific Reports|December 22, 2019
Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitorsKimio Yonesaka, Eiji Iwama, Hidetoshi Hayashi, et al.
Pageof 7